Intravenous gentamicin increased dystrophin production in six of 12 boys with nonsense-mutation DMD but failed to improve strength or function at the doses used
 
Article Highlights:


  • Gentamicin is an injectable aminoglycoside antibiotic that has the potential to increase production of dystrophin, the protein missing in Duchenne MD and diminished in Becker MD. 
  • The antibiotic gentamicin is believed to coax cells to ignore ("read through") an inappropriate genetic signal ("premature stop codon" mutation or "nonsense" mutation) that stops synthesis of the dystrophin protein before a functional protein has been made. 
  • Six of 12 participants who received gentamicin for the longest period of time (six months) showed increased dystrophin production.  
  • No significant improvements in strength or function were seen in any participants, although hints of effectiveness raised the question about whether a higher dose would be beneficial. 
  • An immune response appears to have destroyed newly synthesized dystrophin in one trial participant.

 

 

About gentamicin and MD


 

Gentamicin is an aminoglycoside antibiotic, normally used for fighting infections. Several years ago, it was found that gentamicin is among the compounds that can cause "stop codon read-through," allowing cells to ignore (read through) a stop codon and synthesize a complete and functional protein.


 

In 1999, MDA-supported studies showed that mice missing dystrophin because of a stop codon began producing the protein after treatment with gentamicin. (See Antibiotic Shows Promise as Systemic Treatment for Muscular Dystrophy.) In these mice, the investigators saw some protection against contraction-induced muscle injury and a reduction of serum creatine kinase (CK), an enzyme that leaks out of damaged muscle cells. A reduction in serum CK is generally considered an indication that muscle destruction has slowed.


 

Investigators began to plan studies in humans, but they had to exercise extreme care, because long-term or high-dose gentamicin can cause kidney damage, hearing loss and impairment of balance. (A blood test before gentamicin treatment can reduce the incidence of side effects, Mendell said.)


 

Starting about 2000, investigators cautiously infused the drug in two small, two-week studies in people with DMD, BMD and limb-girdle muscular dystrophy (LGMD), announcing results in 2001. The results of both small studies were confusing: There was no evidence that dystrophin or the targeted LGMD protein increased, but both studies saw marked decreases in blood CK levels, indicating possible slowing of muscle damage. (See "Gentamicin Studies Yield Confusing Results," in Research Updates, Quest, June 2001.)


 

An Italian study of the drug in DMD patients, for which results were announced in 2003, found three out of four participants began producing dystrophin after receiving gentamicin for two six-day periods seven weeks apart.


 

 These early results prompted Mendell and others to continue studying gentamicin as a possible therapy for DMD or BMD. They speculated that a longer course of treatment, accompanied by careful monitoring for drug toxicity, could result in significant dystrophin production.

 

 

Meaning for people with DMD and BMD


 

The data from this latest gentamicin trial show that this stop codon read-through drug can, in some cases, increase dystrophin production, but still more dystrophin will be needed to improve muscle function. 


 

Problems with further increases in gentamicin dosing include: 1) the drug may be toxic in high doses or when given for prolonged periods of time; 2) it has to be given intravenously, which is inconvenient and expensive; 3) only some dystrophin-deficient patients respond to it; and 4) researchers don't yet know what all the factors are that determine this response. 


 

Recently, the oral drug ataluren (PTC124), an experimental stop codon read-through compound, failed to increase the distance people with DMD or BMD could walk in six minutes (see Ataluren Results Disappointing). Detailed analyses of those trial results are not yet available. 


 

It's plausible (although not yet established) that an immune response may be responsible for the failure of gentamicin — and perhaps other stop codon read-through drugs — to sustain enhanced levels of dystrophin and therefore to improve function in DMD and BMD. If this proves to be the case, it may be possible to manipulate the immune system to overcome this barrier to treatment. 

 

 

Please see details on

http://quest.mda.org/news/gentamicin-trial-dmd-shows-mixed-results

 

Views: 70

Reply to This

Replies to This Discussion

Interesting. Would also be interested to know about follow up work and whether there are other ways of administering this drug.

Reply to Discussion

RSS

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service